Is there a Bearish outlook for Biogen Inc. (NASDAQ:BIIB) this week?

January 15, 2018 - By Vivian Park

 Is there a Bearish outlook for Biogen Inc. (NASDAQ:BIIB) this week?
Investors sentiment increased to 1.13 in 2017 Q3. Its up 0.25, from 0.88 in 2017Q2. It is positive, as 59 investors sold Biogen Inc. shares while 283 reduced holdings. 96 funds opened positions while 292 raised stakes. 181.16 million shares or 0.28% more from 180.66 million shares in 2017Q2 were reported.
Rampart Management stated it has 2,936 shares. Moreover, Daiwa Grp Inc Inc has 0.02% invested in Biogen Inc. (NASDAQ:BIIB) for 7,806 shares. Waldron L P reported 0.23% stake. First Long Island Invsts Ltd has invested 0.04% in Biogen Inc. (NASDAQ:BIIB). Bainco International reported 0.7% stake. Morgan Stanley reported 0.1% in Biogen Inc. (NASDAQ:BIIB). Argent Cap Management Ltd Liability Company reported 131,472 shares. Intact Inv Mgmt Inc has invested 0.02% in Biogen Inc. (NASDAQ:BIIB). First Personal Svcs holds 391 shares or 0.03% of its portfolio. 8,433 were reported by Victory Capital Mgmt. Comml Bank Of America De holds 0.12% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 2.42M shares. Lingohr And Partner Asset Management Gmbh reported 0.52% stake. The California-based First Quadrant Limited Partnership Ca has invested 0.66% in Biogen Inc. (NASDAQ:BIIB). State Of Alaska Department Of Revenue holds 0.03% or 1,840 shares in its portfolio. Centurylink Inv holds 5,620 shares.

Since January 9, 2018, it had 0 insider buys, and 1 insider sale for $1.92 million activity.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Among 31 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Biogen Idec Inc. had 95 analyst reports since July 23, 2015 according to SRatingsIntel. BMO Capital Markets maintained Biogen Inc. (NASDAQ:BIIB) on Wednesday, September 13 with “Market Perform” rating. The firm earned “Neutral” rating on Wednesday, October 25 by UBS. The firm has “Hold” rating given on Monday, July 17 by BMO Capital Markets. Atlantic Securities initiated the shares of BIIB in report on Friday, December 18 with “Overweight” rating. The firm has “Market Perform” rating by BMO Capital Markets given on Wednesday, July 26. The stock of Biogen Inc. (NASDAQ:BIIB) has “Hold” rating given on Tuesday, September 6 by Jefferies. BMO Capital Markets maintained Biogen Inc. (NASDAQ:BIIB) rating on Friday, October 20. BMO Capital Markets has “Hold” rating and $382.0 target. The stock has “Hold” rating by Jefferies on Wednesday, August 30. Robert W. Baird maintained Biogen Inc. (NASDAQ:BIIB) on Friday, March 11 with “Neutral” rating. H.C. Wainwright maintained it with “Buy” rating and $340.0 target in Wednesday, October 25 report. Below is a list of Biogen Inc. (NASDAQ:BIIB) latest ratings and price target changes.

02/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $394.0 Maintain
20/12/2017 Broker: Canaccord Genuity Rating: Hold New Target: $340.0
20/12/2017 Broker: Credit Suisse Rating: Buy New Target: $385.0 Upgrade
27/11/2017 Broker: J.P. Morgan Rating: Buy New Target: $378.0
28/11/2017 Broker: Bernstein Rating: Buy New Target: $318.0 Maintain
27/11/2017 Broker: BMO Capital Markets Rating: Buy New Target: $385.0 Maintain
08/11/2017 Broker: Oppenheimer Rating: Buy New Target: $350.0 Initiate
06/11/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $381 New Target: $386 Maintain
30/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $290.0 Maintain
27/10/2017 Broker: Canaccord Genuity Rating: Hold New Target: $340 Initiates Coverage On

The stock increased 0.86% or $2.88 during the last trading session, reaching $335.95. About 885,516 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since January 15, 2017 and is uptrending. It has underperformed by 11.76% the S&P500.

Biogen Inc., a biopharmaceutical company, discovers, develops, makes, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company has market cap of $71.05 billion. The firm offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis ; FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It has a 20.64 P/E ratio. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies.

More important recent Biogen Inc. (NASDAQ:BIIB) news were published by: Bostonglobe.com which released: “Biogen shares drop after Alzheimer’s drug trial setback” on December 21, 2017, also Gurufocus.com published article titled: “Biogen Inc (BIIB) CEO Michel Vounatsos Bought $250029 of Shares”, Seekingalpha.com published: “Biogen adds to recent up move; shares ahead 2%” on December 20, 2017. More interesting news about Biogen Inc. (NASDAQ:BIIB) was released by: Fool.com and their article: “Will 2018 Be Biogen Inc.’s Best Year Yet?” with publication date: January 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.